Market Overview

UPDATE: Goldman Sachs Downgrades DaVita to Neutral on Near-Term Momentum Slowdown

Share:
Related DVA
DaVita HealthCare Partners Q1 Profit Meets Views
Why Baird Is Upgrading DaVita Healthcare
DaVita HealthCare Partners (DVA) Kent J. Thiry on Q2 2015 Results - Earnings Call Transcript (Seeking Alpha)

Goldman Sachs downgraded DaVita (NYSE: DVA) from Buy to Neutral and maintained a $120.00 price target.

Goldman Sachs noted, "We downgrade DVA to Neutral from Buy as we think the stock is now fairly valued and as we see more upside in other areas of our coverage. While our outlook for core dialysis remains solid and we continue to see strong long-term growth potential in physician (HCP) and dialysis integrated care, we expect slower growth with less upward momentum to our/Street view over the next 12-24 months."

DaVita closed at $119.21 on Thursday.

Latest Ratings for DVA

DateFirmActionFromTo
Apr 2015BairdUpgradesNeutralOutperform
Mar 2015Deutsche BankMaintainsHold
Nov 2014JP MorganMaintainsOverweight

View More Analyst Ratings for DVA
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Downgrades Analyst Ratings

 

Related Articles (DVA)

Get Benzinga's Newsletters